The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome
ABSTRACT Acarbose is a safe and effective medication for type 2 diabetes that inhibits host glucoamylases to prevent starch digestion in the small intestines and thus decrease postprandial blood glucose levels. This results in an increase in dietary starch in the distal intestine, where it becomes f...
Guardado en:
Autores principales: | Nielson T. Baxter, Nicholas A. Lesniak, Hamide Sinani, Patrick D. Schloss, Nicole M. Koropatkin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5cfdaeb26567482d832f9c9bc68e2687 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Erratum for Baxter et al., “The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome”
por: Nielson T. Baxter, et al.
Publicado: (2019) -
MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Na Wang, et al.
Publicado: (2019) -
A Combination Approach in Inhibiting Type 2 Diabetes-Related Enzymes Using <i>Ecklonia radiata</i> Fucoidan and Acarbose
por: Blessing Mabate, et al.
Publicado: (2021) -
Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome
por: Tanja V. Maier, et al.
Publicado: (2017) -
Effects of Soy Isoflavones, Resistant Starch and Antibiotics on Polycystic Ovary Syndrome (PCOS)-Like Features in Letrozole-Treated Rats
por: Geethika S. G. Liyanage, et al.
Publicado: (2021)